<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01423370</url>
  </required_header>
  <id_info>
    <org_study_id>YHD1023-201</org_study_id>
    <nct_id>NCT01423370</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of YHD1023 in Erectile Dysfunction</brief_title>
  <official_title>Multi-center, Randomized, Double-blind, Placebo/Active-controlled, Phase II Clinical Trial to Assess the Safety and Efficacy of YHD1023 in Patients With Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety and efficacy of oral YHD1023 5g or 10g on&#xD;
      erectile dysfunction to investigate the optimal recommended dosage. Study period is 12 weeks&#xD;
      including 4weeks of follow-up period without treatment. Study patients will fill in the&#xD;
      international index of erectile function questionnaire and life satisfaction questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the International Index of Erectile Function(IIEF) - Erectile Function(EF) domain score at week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Improved patients from baseline in Question 3 &amp; Question 4 of the International Index of Erectile Function(IIEF) at week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>*Improved: Score increased 1 or more compared to the baseline score&#xD;
Question 3: How many times were you able to insert your penis into your partner's vagina? Scores range from 0(did not have sexual intercourse) to 5(always or most times).&#xD;
Question 4: How many times did your erection last long enough for you to complete intercourse? Scores range from 0(did not have sexual intercourse) to 5(always or most times).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in other Question of International Index of Erectile Function(IIEF) domain at week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Improved patients from baseline in Question 2 &amp; Question 3 of Sexual Encounter Profile(SEP) at week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>*Improved: Response change from &quot;No&quot; at baseline to &quot;Yes&quot; at week 8&#xD;
Question 2: Were you able to insert your penis into your partner's vagina?&#xD;
Question 3: Did your erection last long enough for you to complete intercourse with ejaculation?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Improved patients from baseline in Global Assessment Question(GAQ) at week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>*Improved: Yes response at week 8&#xD;
GAQ: Did the 4 week treatment improve you ability to achieve and maintain your erection?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Life Satisfaction score</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YHD1023</intervention_name>
    <description>5g oral once daily</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YHD1023</intervention_name>
    <description>5g oral twice a day</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YHD1023</intervention_name>
    <description>10g oral once daily</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cialis</intervention_name>
    <description>5mg oral once daily</description>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>Group E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male volunteers of aged 20 years and older with history of organic erectile&#xD;
             dysfunction of at least 6 months duration&#xD;
&#xD;
          -  Anticipate having the same adult female sexual partner, who have no possibility of&#xD;
             being pregnant or breast-feeding and take steps to prevent conception during the study&#xD;
&#xD;
          -  The patient or legally authorized representative must sign a written informed consent,&#xD;
             prior to the any procedure, using a form that is approved by the local Institutional&#xD;
             Review Board after detail explanation of the purpose, contents, and characteristic of&#xD;
             the drug&#xD;
&#xD;
          -  Have Erectile Function(EF) domain score 25 and under as the result of the&#xD;
             International Index of Erectile Function(IIEF)&#xD;
&#xD;
          -  Agree to make at least 4 sexual intercourse attempts on 4 separate days with the&#xD;
             female sexual study party during the 4-week run-in period without medication and at&#xD;
             least 50% of attempts during this period had been unsuccessful due to insufficient&#xD;
             erection or unable to sustain penile rigidity until ejaculation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have history of stroke, myocardial infarction, or Coronary Artery Bypass Graft surgery&#xD;
             within the last 6 months&#xD;
&#xD;
          -  Have history of cardiac failure, unstable angina, or life-threatening arrhythmia&#xD;
             within the last 6 months&#xD;
&#xD;
          -  Shown tachyarrhythmia, heart rate over 100 times/min(e.g. arterial fibrillation,&#xD;
             flutter)&#xD;
&#xD;
          -  Presence of hypotension as evidenced by SBP/DBP &lt; 90/50mmHg or uncontrollable&#xD;
             hypertension as evidenced by SBP/DBP &gt; 170/100mmHg&#xD;
&#xD;
          -  Presence of diagnosed diabetes(HbA1C &gt; 12%)&#xD;
&#xD;
          -  Have history of symptomatic postural hypotension within the last 6 months&#xD;
&#xD;
          -  Have history of spinal cord injury, radical prostatectomy, or pelvic surgery&#xD;
&#xD;
          -  Presence of penile anatomical deformities (e.g. severe penile fibrosis or Peyronie's&#xD;
             disease)&#xD;
&#xD;
          -  Presence of hypogonadism(serum total testosterone under the reference lowest limit)&#xD;
&#xD;
          -  Presence of hepatic impairment(AST or ALT &gt; 3 times of normal upper limit) or renal&#xD;
             impairment(serum creatinine â‰¥ 2.5mg/dl)&#xD;
&#xD;
          -  Have history of severe gastrointestinal hemorrhage within the last 1 year&#xD;
&#xD;
          -  Have history of hematodyscrasia predisposing to priapism(e.g. sickle cell disease,&#xD;
             multiple myeloma, or leukemia) or bleeding disorder&#xD;
&#xD;
          -  Subject who is judged to be ineligible according to their physical checkup(medical&#xD;
             history, physical examination, ECG, laboratory values and etc.) within 56 days prior&#xD;
             to the first administration&#xD;
&#xD;
          -  Concomitant use of one or more of nitrates/nitric oxide(NO) donor(e.g. nitroglycerine,&#xD;
             isosorbid, mononitrate, isosorbid dinitrate, amylnitrate/nitrite, sodium&#xD;
             nitroprusside), Trazodone, cancer chemotherapy, anticoagulants, androgens, or&#xD;
             anti-androgens&#xD;
&#xD;
          -  Use of any PDE-5 inhibitor(e.g. Viagra, Levitra, Cialis, Yaila, or Zydena),&#xD;
             vasodilator self-injection, or other treatments for erectile dysfunction within the&#xD;
             last 2 weeks prior to the study&#xD;
&#xD;
          -  Participated in any other clinical trials within 30 days prior to the first&#xD;
             administration&#xD;
&#xD;
          -  Have history of primary hypoactive sexual desire&#xD;
&#xD;
          -  Subject who is judged to be ineligible by principal investigator or sub-investigator&#xD;
             due to mental disorder or continuous drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nam-Cheol Park, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Busan National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yuhan Corporation</name>
      <address>
        <city>Seoul</city>
        <zip>156-754</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>August 24, 2011</study_first_submitted>
  <study_first_submitted_qc>August 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2011</study_first_posted>
  <last_update_submitted>July 30, 2014</last_update_submitted>
  <last_update_submitted_qc>July 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erectile Dysfunction</keyword>
  <keyword>YHD1023</keyword>
  <keyword>YCD190</keyword>
  <keyword>Cialis</keyword>
  <keyword>Yuhan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

